NCT03504631

Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen

Genotyping and Phenotyping of CYP2D6 as Predictor of Z-endoxifen Plasma Levels in Breast Cancer Patients on Tamoxifen Treatment

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 117 (estimated)
• Sponsor: Trisakti University · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This study is an observational study to determine phenotype and genotype of CYP2D6 as predictors of z-endoxifen concentrations in plasma of outgoing patients treated with tamoxifen for at least 4 months

Detailed description

Tamoxifen is an antiestrogen drug with concentration dependent properties, with z-endoxifen known as active metabolite. Until know therapeutic range for z-endoxifen to improve treatment response was not known. Variation response on tamoxifen can be cause of genetic polymorphism CYP2D6 that can be different between interindividul and ethnic. The aim of this study is to determine phenotype and genotype of CYP2D6 as predictors of z-endoxifen concentrations in plasma of outgoing patients treated with tamoxifen for at least 4 months

Conditions

• Breast Cancer Female

Interventions

Type	Name	Description
OTHER	No intervention	no intervention

Timeline

• Start date: 2017-10-01
• Primary completion: 2018-10-01
• Completion: 2018-12-01
• First posted: 2018-04-20
• Last updated: 2018-04-24

Locations

1 site across 1 country: Indonesia